Digestive Diseases and Sciences

, Volume 58, Issue 6, pp 1790–1796

Thrombocytosis and Hepatocellular Carcinoma

Original Article



Thrombocytopenia has been reported to be both a risk factor for hepatocellular carcinoma (HCC) development as well as a prognostic factor. Many HCCs also occur in presence of normal platelets.


To examine a cohort of HCC patients with associated thrombocytosis.


Records were examined of a cohort of 634 biopsy-proven and randomly presenting HCC patients without thrombocytopenia.


In the total cohort, 52 patients were identified with thrombocytosis (platelet levels >400 × 109/L) and compared with 582 patients with normal platelet values. The average tumor sizes were 13.1 versus 8.8 cm (p < 0.0001), and their total average bilirubin levels were 0.9 versus 1.5 (p = 0.02), comparing thrombocytosis patients versus normal platelet count HCC patients. These differences were even more pronounced in patients with HCC sizes >5 cm. Thrombocytosis patients were younger and had less cirrhosis, but similar percent with hepatitis B or C or alcohol consumption.


Thrombocytosis in association with HCC occurs in patients with larger tumor sizes and better liver function.


HCC Size Thrombocytosis Portal vein thrombosis 



Hepatocellular carcinoma




Portal vein thrombosis






White blood count


Gamma glutamyltranspeptidase


Prothrombin time




Standard deviation


Computerized axial tomography


× 103

Platelet units

× 109/L

Bilirubin values



  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Establishment of world-wide burden of cancer in 2008: GLOBCAN 2008. Int J Cancer. 2010;127:2893–2917.PubMedCrossRefGoogle Scholar
  2. 2.
    Kew MC. Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 2010;58:273–277.CrossRefGoogle Scholar
  3. 3.
    Beasely RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and HBV: a prospective study of 22,000 men in Taiwan. Lancet. 1981;22:1129–1133.CrossRefGoogle Scholar
  4. 4.
    Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis. 2010;31:71–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Yu SZ, Chen G. Blue-green algae toxins and liver cancer. China J Cancer Res. 1994;6:9–17.CrossRefGoogle Scholar
  6. 6.
    Zhou TL, Yu SZ. Laboratory study on the relationship between drinking water and hepatoma. Quantitative evaluation using GGT method. Zhonghua Yu Fang Yi Xue Za Zhi. 1990;234:203–205.Google Scholar
  7. 7.
    Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 2003;23:405–440.PubMedCrossRefGoogle Scholar
  8. 8.
    Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348–1355.PubMedCrossRefGoogle Scholar
  9. 9.
    Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212–2222.PubMedCrossRefGoogle Scholar
  10. 10.
    Kumada T, Toyoda H, Kiriyama S, et al. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol. 2010;82:539–545.PubMedCrossRefGoogle Scholar
  11. 11.
    Lok AS, Seeff LB, Morgan TR, HALT-C Trial Group, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148.PubMedCrossRefGoogle Scholar
  12. 12.
    Carr BI, Guerra V, Pancoska P. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology.. 2012;83:339–345.PubMedCrossRefGoogle Scholar
  13. 13.
    Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P. Small hepatocellular carcinomas and thrombocytopenia. Oncology. 2012;83:331–338.PubMedCrossRefGoogle Scholar
  14. 14.
    Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinic-histopathologic study of 804 North American patients. Am J Clin Pathol. 1996;105:65–75.PubMedGoogle Scholar
  15. 15.
    Okuda K, Nakashima T, Kojiro M, et al. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology. 1989;97:140–146.PubMedGoogle Scholar
  16. 16.
    Trevisani F, D’Intino PE, Caraceni P, et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer. 1995;75:2220–2232.PubMedCrossRefGoogle Scholar
  17. 17.
    Truant S, Boleslawsky E, Duhamel A, et al. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol. 2012. Epub. 08/03/2012.Google Scholar
  18. 18.
    Trousseau A, Bazine V, Cormack J. Lectures on Clinical Medicine. USA: R. Hardwicke; 1867.Google Scholar
  19. 19.
    Riess L. Zur pathologischen anatomie des blutes. Arch Anat Physiol Wissensch Med. 1872;39:237–249.Google Scholar
  20. 20.
    Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Int Med. 1964;114:497–500.CrossRefGoogle Scholar
  21. 21.
    Hwang SJ, Luo JC, Li CP, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10:2472–2477.PubMedGoogle Scholar
  22. 22.
    Chen CC, Chang JY, Liu KJ, et al. Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis. Ann Oncol. 2005;16:988–989.PubMedCrossRefGoogle Scholar
  23. 23.
    Nickerson HJ, Silberman TL, McDonald TP. Hepatoblastoma, thrombocytosis, and increased thrombopoietin. Cancer. 1980;45:315–317.PubMedCrossRefGoogle Scholar
  24. 24.
    Hsiao CC, Chuang JH, Tiao MM, et al. Patterns of hepatoblastoma and hepatocellular carcinoma in children after universal hepatitis B vaccination in Taiwan: a report from a single institution in southern Taiwan. J Pediatr Hematol Oncol. 2009;31:91–96.PubMedCrossRefGoogle Scholar
  25. 25.
    Kuo CY, Liu HC, Chang MH, et al. Hepatoblastoma in infancy and childhood: a clinical and pathological study of 32 cases. Zhonghua Min Guo Xiao. 1991;32:79–87.Google Scholar
  26. 26.
    Komura E, Matsumura T, Kato T, et al. Thrombopoietin in patients with hepatoblastoma. Stem Cells. 1998;16:329–333.PubMedCrossRefGoogle Scholar
  27. 27.
    Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610–618.PubMedCrossRefGoogle Scholar
  28. 28.
    Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–590.PubMedCrossRefGoogle Scholar
  29. 29.
    Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interactions in solid tumors. Int J Cancer. 2012;130:2747–2760.PubMedCrossRefGoogle Scholar
  30. 30.
    Cho MS, Bottsford-Miller J, Vasquez HG, et al. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012. Epub. 09/10/2012.Google Scholar
  31. 31.
    Peterson JE, Zurakowski D, Italiano JE Jr, et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15:265–273.PubMedCrossRefGoogle Scholar
  32. 32.
    Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol. 2001;13:791–801.PubMedCrossRefGoogle Scholar
  33. 33.
    Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond). 2000;99:207–214.CrossRefGoogle Scholar
  34. 34.
    Nalesnik MA, Michalopoulos GK. Growth factor pathways in development and progression of hepatocellular carcinoma. Front Biosci (School Educ). 2012;4:1487–1515.CrossRefGoogle Scholar
  35. 35.
    Yang ZF, Ho DW, Lau CK, et al. Platelet activation during tumor development, the potential role of BDNF–TrkB autocrine loop. Biochem Biophys Res Commun. 2006;346:981–985.PubMedCrossRefGoogle Scholar
  36. 36.
    Zhou J, Tang YZ, Fan J, et al. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol. 2000;126:57–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Gotzmann J, Fischer AN, Zoler M, et al. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene. 2006;25:3170–3185.PubMedCrossRefGoogle Scholar
  38. 38.
    Stock P, Monga D, Tan X, et al. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther. 2007;6:1932–1941.PubMedCrossRefGoogle Scholar
  39. 39.
    Maass T, Thieringer FR, Mann A, et al. Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer. 2011;128:1259–1268.PubMedCrossRefGoogle Scholar
  40. 40.
    Okada H, Honda M, Campbell JS, et al. Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res. 2012. Epub. 05/31/2012.Google Scholar
  41. 41.
    Campbell JS, Hughes SD, Gilbertson DG, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis and hepatocellular carcinoma. Proc Natl Acad Sci USA. 2005;102:3389–3394.PubMedCrossRefGoogle Scholar
  42. 42.
    Soll C, Jang JH, Riener MD, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology. 2010;51:1244–1254.PubMedCrossRefGoogle Scholar
  43. 43.
    Lesurtel M, Clavien P-A. Serotonin: a key molecule in acute and chronic liver injury. Clin Res Hepatol Gastroenterol. 2012. Epub. 06/29/2012.Google Scholar
  44. 44.
    Gauglhofer C, Sagmeister S, Schrottmaier W, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology. 2011;53:854–864.PubMedCrossRefGoogle Scholar
  45. 45.
    Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2001;12:56.CrossRefGoogle Scholar
  46. 46.
    French DM, Lin BC, Wang M, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One. 2012;7:e36713.PubMedCrossRefGoogle Scholar
  47. 47.
    Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012;109:E2165–E2172. Epub. 07/02/2012.Google Scholar
  48. 48.
    Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arter Thromb Vasc Biol. 2010;30:2362–2367.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Nutritional CarcinogenesisIRCCS “S. de Bellis”, National Institute for Digestive DiseasesCastellana GrotteItaly
  2. 2.Department of EpidemiologyIRCCS “S. de Bellis”, National Institute for Digestive DiseasesCastellana GrotteItaly

Personalised recommendations